IGRA screening in biologics: safe and reliable, but not perfect
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Introduction
Systemic biologic agents can increase the risk of reactivation of latent tuberculosis (TB). Prior to initiation, screening for latent TB using an interferon-γ (IFN-γ) release assay (IGRA) is recommended. There is concern that false negative IGRAs may be more likely in this context.
Methods
This retrospective analysis of IGRA, specifically TSPOT.TB, results and outcomes of patients already on or due to start biologics identifies the rate of TB reactivation in a low TB incidence setting. Additionally, we estimate the negative predictive value (NPV) of IGRAs in this population.
Results
Patients on biologics were more likely to have a negative IGRA result than patients not on biologics. There was no statistically significant change in conversion or reversion rates between groups. Of 9263 patients on biologics, 19 developed active TB after starting biologics at an incidence of 55.1 per 100,000 patient years. This occurred despite screening in half of the 16 patients for whom we were able to review medical records. Most drugs implicated were known to be high risk, although rituximab and natalizumab were being taken by 5 patients and 1 patient respectively. The TSPOT.TB NPV was 99.20% and dropped only slightly to 99.17% when we simulated an approach where all borderline IGRA results were regarded as being negative.
Conclusion
Negative IGRA results confer a low risk of subsequent active TB in patients on biologics in a low incidence setting. However, continued awareness is needed given that a number of active TB cases will have had a prior negative result.
Systemic biologic agents can increase the risk of reactivation of latent tuberculosis (TB). Prior to initiation, screening for latent TB using an interferon-γ (IFN-γ) release assay (IGRA) is recommended. There is concern that false negative IGRAs may be more likely in this context.
Methods
This retrospective analysis of IGRA, specifically TSPOT.TB, results and outcomes of patients already on or due to start biologics identifies the rate of TB reactivation in a low TB incidence setting. Additionally, we estimate the negative predictive value (NPV) of IGRAs in this population.
Results
Patients on biologics were more likely to have a negative IGRA result than patients not on biologics. There was no statistically significant change in conversion or reversion rates between groups. Of 9263 patients on biologics, 19 developed active TB after starting biologics at an incidence of 55.1 per 100,000 patient years. This occurred despite screening in half of the 16 patients for whom we were able to review medical records. Most drugs implicated were known to be high risk, although rituximab and natalizumab were being taken by 5 patients and 1 patient respectively. The TSPOT.TB NPV was 99.20% and dropped only slightly to 99.17% when we simulated an approach where all borderline IGRA results were regarded as being negative.
Conclusion
Negative IGRA results confer a low risk of subsequent active TB in patients on biologics in a low incidence setting. However, continued awareness is needed given that a number of active TB cases will have had a prior negative result.
Date Issued
2022-11-28
Date Acceptance
2022-08-18
Citation
ERJ Open Research, 2022, 8 (4), pp.1-9
ISSN
2312-0541
Publisher
European Respiratory Society
Start Page
1
End Page
9
Journal / Book Title
ERJ Open Research
Volume
8
Issue
4
Copyright Statement
©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
License URL
Identifier
https://openres.ersjournals.com/content/8/4/00193-2022.article-info
Publication Status
Published
Date Publish Online
2022-11-28